TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,600,047 | -41.8% | 290,833 | -0.0% | 0.01% | -36.4% |
| Q2 2023 | $4,468,393 | -28.3% | 290,911 | +5.0% | 0.02% | -35.3% |
| Q1 2023 | $6,230,000 | +21.0% | 277,012 | +13.2% | 0.03% | +13.3% |
| Q4 2022 | $5,148,396 | -15.4% | 244,812 | -0.8% | 0.03% | -25.0% |
| Q3 2022 | $6,082,000 | +5.7% | 246,849 | +3.9% | 0.04% | +14.3% |
| Q2 2022 | $5,756,000 | -5.3% | 237,551 | +0.8% | 0.04% | +16.7% |
| Q1 2022 | $6,076,000 | -15.0% | 235,774 | +2.3% | 0.03% | -14.3% |
| Q4 2021 | $7,151,000 | +75.3% | 230,369 | +36.9% | 0.04% | +66.7% |
| Q3 2021 | $4,080,000 | +1107.1% | 168,250 | +1258.2% | 0.02% | +950.0% |
| Q4 2020 | $338,000 | – | 12,388 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |